Research published today in the jou...
Research published today in the journal Atherosclerosis supports the feasibility, immuno-genicity, and safety of CETi-1 (AVANT Immunotherapeutics, Needham, MA). The consequence is designed to elicit antibodies that bind and inhibit the activity of CETP blocking the ability of that protein to transfer cholesterol from HDL to LDL causing HDL cholesterol on a levels to rise. The dose-ranging,
|